Location History:
- Los Altos, CA (US) (2001 - 2003)
- Santa Ana, CA (US) (2004)
- Phoenix, AZ (US) (2006)
- Balboa Island, CA (US) (2006)
Company Filing History:
Years Active: 2001-2006
Title: Innovations of Andrew S Little: A Pioneer in Adenoviral Vector Technology
Introduction
Andrew S Little is a notable inventor based in Phoenix, Arizona, recognized for his contributions to the field of adenoviral vector technology. With a total of five patents, Andrew has made significant advancements in methods targeting specific cell types for therapeutic applications.
Latest Patents
Among his latest patents, Andrew S Little has developed pivotal technologies including "Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof." This patent encompasses replication-competent adenoviral vectors designed to target cells expressing alpha-fetoprotein (AFP). These vectors are engineered with adenoviral genes essential for replication controlled by an AFP-transcriptional regulatory element. Additionally, he holds a patent for "Compositions comprising tissue specific adenoviral vectors" which details host cell specific adenovirus vehicles aimed at effectively transfecting target host cells. These compositions include replication competent adenovirus regulated by a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.
Career Highlights
Andrew has had an impactful career working with esteemed companies such as Cell Genesys, Inc. and Calydon, Inc. His work in these organizations has propelled advancements in viral vector technology, contributing to the development of targeted gene therapies and innovative treatment methods.
Collaborations
Throughout his career, Andrew has collaborated with several notable professionals in the field. Among his coworkers are Daniel R Henderson and Eric R Schuur, both of whom have contributed to advancing research and innovation in viral vectors.
Conclusion
With his focus on adenoviral vector technology and a remarkable portfolio of patents, Andrew S Little continues to be a prominent figure in the realm of biomedical innovation. His research not only enhances our understanding of targeted therapies but also paves the way for future developments in gene therapy applications.